Fenbendazole

Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1].

Product Specifications

CAS Number

[43210-67-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; HIF/HIF Prolyl-Hydroxylase; Microtubule/Tubulin; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/fenbendazole.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : 10 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(OC)NC1=NC2=CC=C(SC3=CC=CC=C3)C=C2N1

Molecular Formula

C15H13N3O2S

Molecular Weight

299.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8 (1) :11926.|[2]Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb;33 (2) :355-62.|[3]Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10;22 (2) :121-34.